A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Mayo Clinic
Neonc Technologies, Inc.
ImmunityBio, Inc.
Inhibrx Biosciences, Inc
Tempest Therapeutics
Xencor, Inc.
NuCana plc
OncoC4, Inc.
Aprea Therapeutics
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Inhibrx Biosciences, Inc
Salubris Biotherapeutics Inc
Eli Lilly and Company
Pliant Therapeutics, Inc.
Atreca, Inc.
University of Florida
Fate Therapeutics
Xencor, Inc.
Gossamer Bio Inc.
Incyte Corporation
MultiVir, Inc.
Incyte Corporation
Eli Lilly and Company